Journal of chemotherapy
-
Journal of chemotherapy · Dec 2013
Observational StudyClinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.
To explore clinical outcomes and cardiac safety of continuous antiHer2 therapy. ⋯ Continuous antiHer2 therapy provides good clinical outcomes, especially in those patients who received lapatinib. Cardiac dysfunction was a rare event, reversible, associated to trastuzumab and not related to treatment duration.